Ixazomib Citrate Global Patent Coverage & Expiry Overview

Track protection status across key markets to assess launch feasibility.

Start your free 7-Day Trial! Book a demo to explore our global patent data.

It is formulated by 1 pharmaceutical company such as TAKEDA PHARMS USA. It is marketed under 1 brand name, including NINLARO. Available in 3 different strengths, such as EQ 2.3MG BASE, EQ 3MG BASE, EQ 4MG BASE, and administered through 1 route including CAPSULE;ORAL.

Strategic Dashboard

info

insightsStrategic Insights

Sourcing & Feasibility

check_circle API availability: autorenew Loading API feasibility...

groups Licensing: 1 potential partners

calendar_todayUS Launch window: autorenew Loading launch window...

timeline Key Patent Barrier & Expiry Timeline

autorenew Loading patent barriers...

factoryGeneric Manufacturer Snapshot

autorenew Loading manufacturers...

gavelRisk & Opportunity Summary

dangerous Risk: autorenew Loading risk analysis...

watch_later Watch: autorenew Loading watch analysis...

rocket_launch Opportunity: autorenew Loading opportunity analysis...

Country

flag

Legal Status

gavel

Expiry From

calendar_today

Expiry To

calendar_today

Access Global Patent Data

Stay ahead with worldwide patent expiry and latest updates.

✓ Comprehensive global patent expiry timelines

✓ Full patent family details and status updates

Unlock Global Patents

Orange Book Drug Approval Timeline

FDA approval history for this ingredient

NDA (New Drug Application) ANDA (Generic Application)

Access Global Exclusivity and Patent Expiry Extensions

Stay ahead with worldwide patent expiry insights, exclusivity data, and latest updates.

✓ Comprehensive global patent expiry timelines

✓ Full patent family details and status updates

✓ Latest exclusivity data and extensions

Unlock Global Access

US Orange Book Patents Expiration Timeline

Key expiration dates for US patents covering this ingredient

View Global Patents Expiration Timeline

Stay ahead with worldwide patent expiry insights, market data, and research updates.

✓ Comprehensive global patent expiry timelines

✓ Full patent family details and status updates

Unlock Global Patent Timeline

Orange Book Drug Strengths

Latest drug strengths approved by FDA

Strength	Route of Administration	Companies	Latest Approval Date

Orange Book Patents

Patents approved by the FDA for the ingredient

	Patent Number	Publication Date	Legal Status	Patent Expiry Date
{"application_id":"49328","ingredient":"IXAZOMIB CITRATE","trade_name":"NINLARO","family_id":"e690025e537c49ce9071","publication_number":"US8530694B2","cleaned_patent_number":"8530694","drug_product_flag":"Y","drug_substance_flag":"Y","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2027-08-06","publication_date":"2013-09-10","legal_status":"Granted"}	US8530694B2 Molecular Formulation	10 Sep, 2013	Granted	06 Aug, 2027
{"application_id":"49326","ingredient":"IXAZOMIB CITRATE","trade_name":"NINLARO","family_id":"e690025e537c49ce9071","publication_number":"US7687662B2","cleaned_patent_number":"7687662","drug_product_flag":"Y","drug_substance_flag":"Y","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2027-08-06","publication_date":"2010-03-30","legal_status":"Granted"}	US7687662B2 Molecular Formulation	30 Mar, 2010	Granted	06 Aug, 2027
{"application_id":"49327","ingredient":"IXAZOMIB CITRATE","trade_name":"NINLARO","family_id":"e690025e537c49ce9071","publication_number":"US8003819B2","cleaned_patent_number":"8003819","drug_product_flag":"Y","drug_substance_flag":"Y","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2027-08-06","publication_date":"2011-08-23","legal_status":"Granted"}	US8003819B2 Molecular Formulation	23 Aug, 2011	Granted	06 Aug, 2027
{"application_id":"49275","ingredient":"IXAZOMIB CITRATE","trade_name":"NINLARO","family_id":"e690025e537c49ce9071","publication_number":"US8871745B2","cleaned_patent_number":"8871745","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2027-08-06","publication_date":"2014-10-28","legal_status":"Granted"}	US8871745B2	28 Oct, 2014	Granted	06 Aug, 2027
{"application_id":"49451","ingredient":"IXAZOMIB CITRATE","trade_name":"NINLARO","family_id":"f18b1e46d7fb4d82a9ee","publication_number":"US8859504B2","cleaned_patent_number":"8859504","drug_product_flag":"Y","drug_substance_flag":"Y","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2029-06-16","publication_date":"2014-10-14","legal_status":"Granted"}	US8859504B2 Molecular Formulation	14 Oct, 2014	Granted	16 Jun, 2029
{"application_id":"49346","ingredient":"IXAZOMIB CITRATE","trade_name":"NINLARO","family_id":"f18b1e46d7fb4d82a9ee","publication_number":"US9175017B2","cleaned_patent_number":"9175017","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2029-06-16","publication_date":"2015-11-03","legal_status":"Granted"}	US9175017B2	03 Nov, 2015	Granted	16 Jun, 2029
{"application_id":"49325","ingredient":"IXAZOMIB CITRATE","trade_name":"NINLARO","family_id":"e690025e537c49ce9071","publication_number":"US7442830B1","cleaned_patent_number":"7442830","drug_product_flag":"Y","drug_substance_flag":"Y","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2029-11-20","publication_date":"2008-10-28","legal_status":"Granted"}	US7442830B2 Molecular Formulation	28 Oct, 2008	Granted	20 Nov, 2029

Recent Clinical Trials

Latest clinical trials and research studies for this ingredient

NCT ID	Title	Status	Phase	Conditions	Start Date	Completion Date

API Suppliers/Manufacturer (Branded/Generic companies)

Manufacturing Locations

Filter by Country

View Complete Supplier List

Unlock access to all suppliers of Ixazomib Citrate

✓ Access a comprehensive list of global suppliers

✓ Get information on each supplier

Unlock Suppliers

Note: Patent expirations and exclusivity timelines are dynamic and may shift based on litigation, regulatory extensions, and maintenance filings. Regular monitoring is advised.